We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Type 1 Diabetes Risk Reflected in Gut Microbiome

By LabMedica International staff writers
Posted on 06 Sep 2019
Type 1 diabetes mellitus (T1D) is an autoimmune disorder characterized by the destruction of insulin-producing ß-cells in the pancreas, resulting in a life-long dependence on exogenous insulin. More...
T1D is an autoimmune condition that can develop at any age.

According to recent estimates, there are 1.3 million adults in the USA living with diabetes. Although the causes of type 1 diabetes are not yet known, there are many risk factors for this metabolic condition. Genetic risk factors for T1D have been identified in over 50 diverse genetic loci, but the greatest genetic determinant of T1D remains the human leukocyte antigen (HLA) region.

A team of scientists including those from Linköping University (Linköping, Sweden) examined data available from the All Babies in Southeast Sweden (ABIS) study. They conducted the ABIS study with the aim of understanding why children develop conditions that primarily involve the immune system. The ABIS study contains data from questionnaires and biological samples on over 17,000 children born in 1997–1999. As part of the study, scientists collected biological samples "at birth, 1 year, 2–3 years, and 5–6 years of age." The samples included "blood, urine, stool, and hair."

To enable the comparison of different levels of HLA risk for developing T1D autoimmunity, subjects with available HLA genotype data were placed into one of four categories of risk based on their HLA genotype. DNA from each sample was extracted from ~200 mg of stool, using the E.Z.N.A Stool Extraction Kit. DNA used for subsequent polymerase chain reaction (PCR) was quantified and assessed for purity using a NanoDrop spectrophotometer. Amplicons from each sample were pooled and sequenced on the MiSeq platform.

The scientists reported that both the core microbiome and beta diversity differ with HLA risk group and genotype. In addition, protective HLA haplotypes are associated with bacterial genera Intestinibacter and Romboutsia. They found that children with a high genetic risk had a different composition in their gut microbiota and different gut microbiomes than children with a low risk. The authors concluded that the information gained from this type of cohort furthers our understanding of how HLA genetic risk drives changes in the gut microbiome and how genetics may be “setting the stage” for environmental triggers that ultimately lead to T1D autoimmunity. The study was published on August 9, 2019, in the journal Nature Communications.

Related Links:
Linköping University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
HPV Test
Allplex HPV28 Detection
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study design and workflow (Parankusham H, Vanderlip C, Birkenbihl C, et al. A two-stage plasma biomarker algorithm reduces amyloid PET use and the p-Tau217 gray zone. Annals of Clinical and Translational Neurology. Published online October 19, 2026. doi:10.1002/acn3.70560)

Two-Step Blood Testing Approach Reduces Uncertainty in Amyloid Assessment

Blood-based biomarkers offer a more accessible, less expensive way to detect Alzheimer’s-related brain changes than traditional methods such as amyloid-beta positron emission tomography (Aβ-PET).... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image: HETA Quality Control identifies slide quality issues before analysis, while HETA Tumor Detect annotates tumor regions and flags slides likely to contain tumor during scanning. (Photo courtesy of Aignostics)

AI Pathology Platform Targets Workflow Delays and Molecular Test Failures

Pathology laboratories often rely on visual review of tissue slides to assess quality, identify tumors, count mitoses, and estimate tumor content. These tasks can be time-consuming and vary between readers,... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.